What Is Hexarelin?

1. How does hexarelin work?

Hexarelin belongs to the growth hormone-releasing peptide family, or GHRPs. It activates the ghrelin-receptor pathway involved in GH secretion. GH then acts on tissues and influences insulin-like growth factor 1, abbreviated IGF-1. Neither a brief GH spike nor a higher IGF-1 result measures newly built muscle.

HGH supplies growth hormone directly. Hexarelin depends on the body’s ability to release it. Sermorelin and CJC-1295 stimulate a different receptor, the GHRH receptor. These differences explain why the compounds appear in different stacks, but cannot identify the best stack for training outcomes.

Hexarelin also binds CD36. Demers and colleagues mapped this binding site in laboratory experiments. CD36 helps cells handle lipids and participates in vascular signaling, which explains the separate interest in hexarelin’s cardiac and metabolic effects. Binding a receptor does not tell us whether repeated use will improve health.

2. What do human hexarelin studies show?

The human literature contains direct measurements relevant to several popular claims. The endpoints range from a few hours of hormone sampling to months of treatment.

These experiments differ in route, population and purpose. A response under anesthesia cannot predict gym performance, and a single injection cannot establish what happens after months of use.

3. Desensitization, muscle growth and fat loss

In Rahim and colleagues’ 16-week study, the average GH response to a test injection fell from 19.1 to 10.5 µg/L·h, about 45%. This measure is the area under the hormone curve, which captures the response over time. Four weeks after treatment stopped, it was 19.4 µg/L·h, close to baseline.

The study found no significant improvement in lean mass, body fat or bone mineral density. IGF-1 also did not change significantly. The reduced responsiveness was partial and reversible, but the experiment did not compare bodybuilding cycles or demonstrate that scheduled breaks produce muscle gains.

Fat-loss claims also draw on Rodrigue-Way and colleagues’ cell and mouse experiments. Hexarelin reduced lipid content in cultured fat cells and produced changes in mitochondria and thermogenic markers. Some effects depended on CD36. Those findings concern cellular fuel handling; they do not supply a human weight-loss percentage.

A useful body-composition study would track muscle, fat and strength under comparable nutrition and training conditions. Neither a post-injection hormone peak nor a cellular “fat-burning” result supplies those outcomes. There is no dependable estimate of how much muscle a healthy lifter can expect to gain from hexarelin.

4. Does hexarelin improve deep sleep or recovery?

Frieboes and colleagues compared placebo with four nighttime administrations in seven young volunteers. Hexarelin reduced stage 4 sleep during the first half of the night and reduced EEG delta power across the night. Delta power measures slow brain-wave activity associated with deep sleep.

GH and prolactin increased overnight; ACTH and cortisol increased during the first half of the night. This was a small, specific experiment, so it cannot establish that every user or schedule worsens sleep. It does directly undermine the assumption that a larger nighttime GH response guarantees deeper sleep.

Workout recovery needs separate evidence. Less soreness, faster return of strength and tendon healing are different outcomes. The studies discussed here do not establish an effective hexarelin treatment for any of them. A wearable sleep score or a good training week cannot isolate the peptide’s contribution when training load, calories, bedtime or other compounds change simultaneously.

5. Hexarelin and heart health: what was measured?

Hexarelin’s cardiac research is one reason it stands apart from a generic GH-secretagogue discussion. Some human experiments suggest effects that do not depend on an increase in circulating GH.

Broglio and colleagues studied seven healthy adults, seven people with severe GH deficiency and 12 with dilated cardiomyopathy. A single IV administration increased left ventricular ejection fraction in the first two groups, but not in the cardiomyopathy group. Ejection fraction is the proportion of blood the left ventricle pumps out with each beat.

In the bypass-surgery experiment, researchers observed improvements in ejection fraction and cardiac output beginning after 10 minutes and lasting through 90 minutes. Mean arterial pressure also increased. The setting was coronary surgery under general anesthesia, with invasive monitoring.

Neither experiment measured prevention of heart attacks, long-term heart-failure outcomes or survival. They also cannot support using hexarelin to offset cardiovascular harm from anabolic steroids or other performance-enhancing drugs.

Preclinical findings add complexity. Bodart and colleagues observed coronary vasoconstriction in isolated rat hearts exposed to hexarelin. That does not prove a human cardiovascular hazard at a particular dose, but it makes “heart protective” an incomplete description of the research.

6. Hexarelin side effects, cortisol and prolactin

Hexarelin can stimulate hormones besides GH. ACTH signals the adrenal glands to release cortisol; prolactin has reproductive and other functions. Acute changes in these hormones are documented, but a transient laboratory increase does not establish a chronic endocrine disorder.

The 1999 Rahim study examined repeated treatment over 16 weeks. Basal cortisol, 24-hour urinary free cortisol and the prolactin response did not change significantly. The cortisol response to an injection decreased. The authors found no progressive overstimulation of the pituitary-adrenal axis or prolactin secretion under that regimen.

That finding deserves space alongside the acute hormone spikes. It still cannot establish long-term safety across higher exposures, younger athletes or multi-peptide stacks. The available studies cannot provide reliable rates for uncommon complications, diabetes or cancer after prolonged enhancement use.

Product quality creates a separate problem. A purity percentage alone does not establish sterility, correct vial content or an accurate finished dose. FDA’s compounding guidance describes risks from contamination and excess active ingredient, and explains that compounded drugs do not undergo premarket approval for safety, effectiveness or quality.

7. Hexarelin half-life, dosage and cycles

The widely repeated “55-minute half-life” needs its original context. In Imbimbo and colleagues’ human study, GH peaked around 30 minutes and returned to baseline within 240 minutes. The reported 55-minute decline concerned circulating GH. It was not a measurement of hexarelin elimination.

Roumi and colleagues did measure hexarelin itself, reporting an IV half-life of 75.9 ± 9.3 minutes in rats. That value cannot establish human subcutaneous pharmacokinetics. A half-life tracking curve based on either number would need to state what substance, species and route the number describes.

No enhancement dose, fasting window, bedtime schedule or on/off cycle has been validated. Describing a research regimen is different from demonstrating that it delivers a useful benefit with acceptable risk. A schedule intended to preserve a GH response also needs evidence that the preserved response improves the outcome someone wants.

8. Hexarelin vs ipamorelin, GHRP-6, CJC-1295 and HGH

“Stronger” usually refers to a hormone response measured under particular experimental conditions. It cannot rank compounds for muscle gain, sleep or safety.

The original Raun et al. ipamorelin study characterized selectivity in animals, including hormone testing in pigs. It cannot supply long-term comparative safety data in humans. Conversely, hexarelin’s human hormone effects cannot establish that every ipamorelin user avoids those effects.

Combining hexarelin with CJC-1295 adds uncertainty about exposure and attribution. If sleep deteriorates or a laboratory value changes after starting a blend, individual-compound papers cannot identify the responsible ingredient. The actual formulation and every co-administered compound belong in the treatment record.

9. Is hexarelin FDA-approved or banned in sport?

Hexarelin has no FDA-approved medical use. Its entry in the FDA substance registry identifies examorelin and its synonyms; a substance identity record is not a drug approval. Approved products are listed separately in Drugs@FDA.

For tested athletes, WADA’s 2026 Prohibited List explicitly names examorelin (hexarelin) in section S2.2.4. It is prohibited both in and out of competition.

If a clinic proposes hexarelin for a specific goal, ask for the human trial that measured that goal, the expected size of benefit and the plan for assessing adverse effects. For muscle gain, that means body composition and function. For sleep, it means sleep outcomes. A GH blood result answers a narrower question.

10. Hexarelin FAQ

• What is hexarelin used for?

  Researchers have studied hexarelin for GH release and cardiac effects. Sellers promote it for muscle, fat loss and recovery, but it has no FDA-approved medical use and no established enhancement protocol.

• Is hexarelin the same as examorelin or HGH?

  Examorelin is another name for hexarelin. HGH is growth hormone itself; hexarelin stimulates its release. Hexarelin is a peptide, not an anabolic steroid.

• Does hexarelin build muscle or burn fat?

  A 16-week study found no significant improvement in lean mass or total body fat. Cell and mouse fat-metabolism findings do not establish a human fat-loss benefit.

• Does hexarelin cause desensitization?

  Yes. Human research documents a reduced GH response during repeated treatment, with recovery after withdrawal. It does not establish that weekend breaks or a particular cycle preserve physique benefits.

• Does hexarelin improve sleep?

  The small controlled study discussed here found less stage 4 sleep early in the night and lower overnight EEG delta power. More GH did not translate into deeper sleep in that experiment.

• What is hexarelin's half-life?

  The frequently cited 55-minute value refers to GH decline after hexarelin administration. A separate study measured roughly 76 minutes for hexarelin in rats. Neither establishes the peptide's half-life after a human subcutaneous injection.

• What is the best hexarelin dosage or cycle?

  No dose or cycle has been validated for healthy-adult muscle gain, fat loss or recovery. Experimental regimens cannot establish a safe or effective self-injection schedule.

• Is hexarelin better than ipamorelin?

  Human trials have not established a winner for physique or recovery. Hexarelin has human evidence of cortisol and prolactin stimulation; ipamorelin's original selectivity evidence came from animals.

• Does hexarelin protect the heart?

  Small human experiments found short-term changes in cardiac pumping function in some settings. They did not establish prevention of heart attacks, longer survival or protection against other performance-enhancing drugs.

• Is hexarelin allowed in tested sport?

  WADA's 2026 Prohibited List explicitly names examorelin (hexarelin) among GH-releasing peptides prohibited both in and out of competition.

11. Sources